The GLP-1 drug semaglutide — sold as Ozempic and Wegovy — has been linked to an unexpected mental-health signal: fewer psychiatric hospitalizations among people with bipolar disorder. But the finding comes with real limits.
Researchers at Griffith University analyzed nationwide Swedish data on nearly 15,000 people with bipolar disorder over a 15-year span (2009–2024). Those prescribed semaglutide had a 21% lower risk of psychiatric hospitalization. The work appeared in Acta Psychiatrica Scandinavica.
The caveats matter a lot
This is an observational study, so it shows association, not causation — people prescribed semaglutide may differ in ways that affect hospitalization risk. And the benefit was specific to semaglutide: the same pattern was not seen with other GLP-1 drugs like liraglutide or dulaglutide, so this shouldn’t be read as a class-wide effect. It also measured hospitalizations, not a direct measure of mood symptoms.
Why it matters
The proposed idea is that GLP-1 signaling may protect the brain by dampening inflammation and cellular stress linked to bipolar disorder — a plausible but unproven mechanism. It’s a genuinely interesting lead worth testing in randomized controlled trials, which the authors call for. For now it’s a hypothesis-generating signal, not a reason to change treatment. This summarizes research and is not medical advice.